Buprenorphine Tablet
FDA Label NDC 70518-1557

59 label sections · Submitted to the FDA by Remedyrepack Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Remedyrepack Inc. for the product Buprenorphine (NDC 70518-1557). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 important dosage and administration instructions, 2.2 patient access to an opioid overdose reversal agent for the emergency treatment of opioid overdose, 2.3 induction, 2.4 maintenance, 2.5 method of administration, 2.6 clinical supervision, 2.7 patients with severe hepatic impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.